Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation

Rupali Roy*, Andrew M. Evens, David Patton, Lillia Gallot, Annette Larson, Alfred Rademaker, Jeffrey Cilley, Stewart Spies, Daina Variakojis, Leo I. Gordon, Jane N. Winter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation'. Together they form a unique fingerprint.

Medicine & Life Sciences